Vetoquinol completes acquisition of Profender® and Drontal®
Vetoquinol has completed its acquisition of the Profender and Drontal product families.
Vetoquinol has completed its acquisition of Profender® and Drontal® product families, previously owned by Bayer Animal Health.
The acquisition is related to Elanco’s acquisition of Bayer AG’s animal health business, finalised on 1 August 2020. The Profender and Drontal families of products are spot-on and tablet de-wormer products for cats and dogs.
Vetoquinol CEO Matthieu Frechin said: "We are extremely pleased to share the completion of the acquisition of the Profender®and Drontal®product lines. These two strong brands fit perfectly at the core of Vetoquinol strategy.
“From now on, they will significantly increase the size of our business and our visibility in the parasiticide segment, one of our strategic therapeutic areas. Also, effectively immediately, these products and brands strengthen our portfolio of Essentials, the engine of our growth. I am proud of the Vetoquinol teams whom made this deal happen despite the challenging circumstances under the COVID global context.”
Elanco’s acquisition of Bayer Animal Health is valued at $6.89 billion. The transaction elevates Elanco’s pet business to approximately 50 per cent of revenues and almost triples the company’s international pet health business.
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
